This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Jun 21;371(9630):2061-2.

doi: 10.1016/S0140-6736(08)60895-8.

Endothelin-receptor antagonism: the future is bright

Neeraj Dhaun¹, David J Webb

Affiliations

PMID: 18572063
DOI: 10.1016/S0140-6736(08)60895-8

Comment

Endothelin-receptor antagonism: the future is bright

Neeraj Dhaun et al. Lancet. 2008.

. 2008 Jun 21;371(9630):2061-2.

doi: 10.1016/S0140-6736(08)60895-8.

Authors

Neeraj Dhaun¹, David J Webb

Affiliation

¹ Queen's Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK. bean.dhaun@ed.ac.uk

PMID: 18572063
DOI: 10.1016/S0140-6736(08)60895-8

No abstract available

PubMed Disclaimer

Comment on

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Galiè N, et al. Lancet. 2008 Jun 21;371(9630):2093-100. doi: 10.1016/S0140-6736(08)60919-8. Lancet. 2008. PMID: 18572079 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information